Nasal Vaccines Are Commercially High Risk, Perhaps High Reward

Jun 13

Written By Guest User

from The Scientist, June 2022 Issue 2

https://www.the-scientist.com/bio-business/nasal-vaccines-are-commercially-high-risk-perhaps-high-reward-70068

Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine

CyanVac Announces Data from Preclinical Studies of Intranasal PIV5-based COVID-19 Vaccine Candidate CVXGA1